Treatment with Circadin® for 13 weeks ensures a continued effect of Circadin® in this period. Circadin® is, however, a symptomatic treatment. After discontinuation of Circadin®, the beneficial effects remain for some time before sleep variables (time to sleep onset, quality of sleep, etc.) gradually return to pre-treatment levels12. Stopping Circadin® treatment does not cause rebound insomnia. Treatment can be restarted when / if the insomnia symptoms reoccur12 31 49 56.
A study that was published in 2011 supports the efficacy and safety of Circadin® in primary insomnia patients aged 20-80 throughout 6-12 months of continuous therapy. Circadin® discontinuation even after 12 months was not associated with adverse events, withdrawal symptoms or suppression of endogenous melatonin production, on the contrary, residual benefit was observed20.
Posted in: Drug safety